A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
The purpose of this study is to determine if the study drug is safe and effective in
 preventing hepatic encephalopathy (HE).
Inclusion Criteria:

 -  Must sign an Informed Consent Form

 -  In remission from past HE

 -  Uses appropriate birth control measures

 -  More than or equal to 18 years of age

 -  Must have potential to benefit from treatment

 -  Recent prior HE episodes

 -  Capable and willing to comply with all study procedures

 -  Participant has personal support available

 -  Has a certain Model End Stage Liver Disease (MELD) score

 -  Recent transjugular intrahepatic portosystemic shunt (TIPS) placement or revision

 Exclusion Criteria:

 -  Significant medical conditions, medical conditions that may impact study
 participation, or Investigator decision not to include

 -  Allergies to the study drug or similar drugs

 -  Laboratory abnormalities

 -  Recent participation in another clinical trial

 -  History of non-compliance

 -  Pregnant or at risk of pregnancy, or is lactating

 -  Recent alcohol consumption

 -  Active bacterial or viral Infections

 -  Bowel issues

 -  Active malignancy

 -  On a prohibited medication

 -  Liver transplant expected in near term

 -  Lactulose intolerance

 -  Participant shows presence of intestinal obstruction or has inflammatory bowel disease

 -  Ongoing or recent GI bleed